Search results for " Antibodies"

showing 10 items of 383 documents

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

The (2'-5')Oligoadenylate Synthetase is Present in the Lowest Multicellular Organisms, the Marine Sponges. Demonstration of the Existence and Identif…

1995

We have proved the presence of (2'-5')oligoadenylates [(2'-5')An] and oligoadenylate synthetase [(2'-5')An synthetase] in the marine sponge Geodia cydonium. (2'-5')An isolated from sponge crude extract competed with authentic (2'-5')An for binding to polyclonal antiserum against (2'-5')An. HPLC analysis revealed the presence of nucleotides eluting with molecular markers for (2'-5')A oligomers. The biological activity of sponge (2'-5')An was demonstrated by inhibiting the protein biosynthesis in rabbit reticulocyte lysate. The activity of the (2'-5')An synthetase, present in crude sponge extract, was found to be high compared to that in mammalian interferon-treated cell extract. The (2'-5')A…

ReticulocytesBlotting WesternCross ReactionsIn Vitro TechniquesBiochemistrylaw.inventionMiceSpecies SpecificityWestern blotlawAdenine nucleotide2'5'-Oligoadenylate SynthetasemedicineAnimalsChromatography High Pressure LiquidProtein Synthesis InhibitorsAntiserumchemistry.chemical_classificationOligoribonucleotidesbiologymedicine.diagnostic_testAdenine Nucleotides2'-5'-OligoadenylateImmunochemistryBlood Proteinsbiology.organism_classificationBiological EvolutionMolecular biologyPoriferaRatsMolecular WeightSpongeEnzymeBiochemistrychemistryPolyclonal antibodiesbiology.proteinRecombinant DNARabbitsEuropean Journal of Biochemistry
researchProduct

Selection of single-chain antibodies against the VP8* subunit of rotavirus VP4 outer capsid protein and their expression in Lactobacillus casei.

2004

ABSTRACTSingle-chain antibodies (scFv) recognizing the VP8* fraction of rotavirus outer capsid and blocking rotavirus infection in vitro were isolated by phage display. Vectors for the extracellular expression inLactobacillus caseiof one of the scFv were constructed.L. caseiwas able to secrete active scFv to the growth medium, showing the potential of probiotic bacteria to be engineered to express molecules suitable for in vivo antirotavirus therapies.

RotavirusLactobacillus caseiPhage displayvirusesMolecular Sequence Datachemical and pharmacologic phenomenamedicine.disease_causeAntibodies ViralApplied Microbiology and BiotechnologyVirusMicrobiologyCell Linefluids and secretionsPeptide LibraryRotavirusmedicineHumansAmino Acid SequencePeptide libraryEcologybiologyfood and beveragesrespiratory systembiology.organism_classificationPhysiology and BiotechnologyVirologyComplementarity Determining RegionsIn vitroCulture MediaLacticaseibacillus caseiCapsidCapsid ProteinsSingle-Chain AntibodiesFood ScienceBiotechnologyApplied and environmental microbiology
researchProduct

Blockage of cell wall receptors for yeast killer toxin KT28 with antimannoprotein antibodies.

1990

Binding of yeast killer toxin KT28 to its primary cell wall receptor was specifically blocked with polyclonal antimannoprotein antibodies which masked all toxin-binding sites on the surface of sensitive yeast cells. By indirect immunofluorescence, it was shown that KT28 binds to the cell wall mannoprotein and that the toxin resistance of mannoprotein mutants (mnn) of Saccharomyces cerevisiae was due to a lack of killer toxin-binding sites within the yeast cell wall. Structural analysis of acetylated mannoprotein from KT28-resistant mutant strains identified the outer mannotriose side chains as the actual killer toxin-binding domains.

Saccharomyces cerevisiae ProteinsMutantSaccharomyces cerevisiaeFluorescent Antibody TechniqueSaccharomyces cerevisiaeBiologymedicine.disease_causeAntibodiesCell wallCell WallmedicinePharmacology (medical)ReceptorPharmacologyMembrane GlycoproteinsToxinMycotoxinsbiology.organism_classificationYeastKiller Factors YeastCell biologycarbohydrates (lipids)Infectious DiseasesBiochemistryPolyclonal antibodiesbiology.proteinAntibodyResearch Article
researchProduct

IgG1 antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency

2000

Background—In selective IgA deficiency (IgAD), there is no reliable screening test for coeliac disease (CD). Aim—To evaluate the usefulness of IgG1 antiendomysium and IgG antitissue transglutaminase tests for CD diagnosis in IgAD. Methods—IgA and IgG antigliadin antibodies (IgA- and IgG-AGA), IgA and IgG1 antiendomysium antibodies (IgA- and IgG1-EMA), and IgA and IgG antitissue

Screening testbiologyTissue transglutaminaseGastroenterologySelective IgA deficiencymedicine.diseaseEndomysiumCoeliac diseaseAntiendomysium antibodiesmedicine.anatomical_structureImmunopathologyImmunologymedicinebiology.proteinAntibodyGut
researchProduct

Antigenic cell wall mannoproteins in Candida albicans isolates and in other Candida species.

1991

Polyclonal antibodies (pAbs) and monoclonal antibodies (mAbs), raised against mannoprotein components from Candida albicans ATCC 26555 (serotype A) blastoconidia and mycelial cell walls, were used to investigate antigenic similarities among wall mannoproteins from other C. albicans serotype A and B strains, and from C. tropicalis and C. guilliermondii. Radioactively labelled walls isolated from cells grown at either 28 degrees C or 37 degrees C were digested with a beta-glucanase complex (Zymolyase 20T) to release cell-wall-bound mannoproteins. Numerous molecular species with different electrophoretic mobilities were released from the various isolates. Differences appeared to be related to …

SerotypeAntigenicityAntigens FungalHydrolasesMicrobiologyBlastoconidiumMicrobiologyCell wallFungal ProteinsEpitopesSpecies SpecificityCell WallCandida albicansCandida albicansCandidaMembrane GlycoproteinsMolecular massbiologyImmunochemistryAntibodies MonoclonalMembrane Proteinsbiology.organism_classificationCorpus albicanscarbohydrates (lipids)BiochemistrySolubilityPolyclonal antibodiesbiology.proteinJournal of general microbiology
researchProduct

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis

2021

IntroductionThe World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA. Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients’ features, potential pathophysiological mechanisms, timing of appearance of the adverse events, and other critical issues.Materials and MethodsWe performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed (MEDLINE) d…

Settore BIO/17 - Istologiamedicine.medical_specialtyImmunologyMEDLINEvaccine-related thrombosisSettore MED/43 - Medicina LegalePF4 antibodiesInternal medicinePandemicmedicineCOVID 19 Vaccine Vaccine ThrombosisImmunology and AllergyPlateletAdverse effectvaccine complicationsbiologybusiness.industryvaccine adverse effectsRC581-607medicine.diseaseThrombosisPathophysiologyVaccinationbiology.proteinSystematic ReviewImmunologic diseases. AllergyAntibodybusinessCOVID-19 vaccineFrontiers in Immunology
researchProduct

Impact of Mycobacterium tuberculosis Infection on Human B Cell Compartment and Antibody Responses

2022

Tuberculosis (TB) remains one of the most important health challenges worldwide. Control of the TB epidemic has not yet been achieved because of the lack of an effective vaccine and rapid and sensitive diagnostic approaches, as well as the emergence of drug-resistant forms of M. tuberculosis. Cellular immunity has a pivotal role against M. tuberculosis infection, but the role of humoral immunity is still controversial. We analyzed the frequency, absolute counts, and phenotypic and functional subsets of B lymphocytes in the peripheral blood of patients with active TB and subjects with latent infection compared to healthy donors. Moreover, we analyzed serum levels of total Ig and their IgA, I…

Settore MED/04 - Patologia GeneraleSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicapre-existing antibodiestuberculosishumoral immunityGeneral Medicinememory subsetsB lymphocytestuberculosis; B lymphocytes; memory subsets; humoral immunity; pre-existing antibodiesCells; Volume 11; Issue 18; Pages: 2906
researchProduct

RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE

2012

Background: Scientific data provide today the evidence that secondary K-RAS mutations do not occur during anti-EGFR therapy in CRC patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and Methods: we enrolled 39 irinotecan refractory patients who had a clinical benefit after a line of Cetuximab plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were re-treated with the same Cetuximab plus Irinotecan based therapy. Results: Median number of therapeutic lines before accrual was 4. Median inte…

Settore MED/06 - Oncologia MedicaCANCERANTI-EGFR MONOCLONAL ANTIBODIES
researchProduct